Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults
NCT03382405
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
181
Enrollment
INDUSTRY
Sponsor class
Conditions
Cytomegalovirus Infection
Interventions
BIOLOGICAL:
mRNA-1647
BIOLOGICAL:
mRNA-1443
OTHER:
Placebo
Sponsor
ModernaTX, Inc.